Barzilai Merav, Avivi Irit, Amit Odelia
Hematology and Hemato-Oncology Division, Tel Aviv Medical Center, Tel Aviv 6423906, Israel.
Mol Clin Oncol. 2019 Jan;10(1):3-9. doi: 10.3892/mco.2018.1759. Epub 2018 Nov 8.
Hematological malignancy during pregnancy is a rare event, therefore most data on this issue is based on case studies, retrospective studies and expert opinion. The purpose of the present narrative review was to provide an overview of the diagnosis and recommended management of the most common hematological malignancies during pregnancy, based on current literature, with clinical cases, and discussion of the diagnostic and therapeutic options. The therapeutic consensus while coping with hematological malignancies in pregnancy is to salvage the mother, while trying to preserve pregnancy and avoid treatment-related-toxicity to the fetus. In most scenarios, particularly during late trimesters, the goal is to administer the same treatment as outside of pregnancy, if possible. Further research is needed for better evidence-based management.
孕期血液系统恶性肿瘤是一种罕见事件，因此关于这一问题的大多数数据基于病例研究、回顾性研究及专家意见。本叙述性综述的目的是基于当前文献、结合临床病例，对孕期最常见的血液系统恶性肿瘤的诊断及推荐治疗进行概述，并讨论诊断和治疗选择。应对孕期血液系统恶性肿瘤的治疗共识是挽救母亲，同时尽量保留妊娠并避免对胎儿产生治疗相关毒性。在大多数情况下，尤其是在孕晚期，如果可能的话，目标是给予与非孕期相同的治疗。需要进一步研究以实现更好的循证管理。
